Bosutinib (BOS) as third-line therapy for chronic phase (CP) chronic myeloid leukemia (CML) following failure with imatinib (IM) and dasatinib (DAS) or nilotinib (NIL)

被引：0
|
作者：
Brummendorf, T. H.
Cortes, J. E.
Kantarjian, H.
Gambacorti-Passerini, C.
Baccarani, M.
Kim, D.
Zaritskey, A.
Navarro, J.
Rapoport, A.
Dorlhiac-Llacer, P. E.
Milone, J.
Zanichelli, M.
Besson, N.
Leip, E.
Kelly, V.
Khoury, H. J.
机构：
[1] Rhein Westfal TH Aachen, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Aachen, Germany
[2] RWTH, Univ Klinikum Hamburg Eppendorf, Univ Klinikum Aachen, Hamburg, Germany
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] Univ Milano Bicocca, Monza, Italy
[5] Univ Bologna, Bologna, Italy
[6] Seoul St Marys Hosp, Seoul, South Korea
[7] Univ Pavlov, St Petersburg, Russia
[8] Hosp Nacl Edgardo Rebagliati Martins, Lima, Peru
[9] Greenebaum Canc Ctr, Baltimore, MD USA
[10] FMUSP, Hosp Clin, Sao Paulo, Brazil
[11] Inst Trasplante Medula Osea, La Plata, Buenos Aires, Argentina
[12] Univ Sao Paulo, Childrens Inst, Sao Paulo, Brazil
[13] Pfizer Global Res & Dev, Paris, France
[14] Pfizer Inc, Cambridge, MA USA
[15] Emory Univ, Sch Med, Atlanta, GA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.6535
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6535
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Incidence of Hyperglycemia by 3 Years in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib (NIL) or Imatinib (IM) in ENESTnd
    Delphine, Rea
    Gautier, Jean-francois
    Breccia, Massimo
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Kemp, Charisse
    Gao, Haitao
    Piccolo, Carmen
    Larson, Richard A.
    Hochhaus, Andreas
    BLOOD, 2012, 120 (21)
  • [22] Glucose Metabolism (GM) Changes in Nondiabetic Patients (Pts) With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib (NIL) or Imatinib (IM)
    Gautier, Jean-Francois
    Rea, Delphine
    Saglio, Giuseppe
    Hughes, Timothy P.
    Kantarjian, Hagop M.
    Kemp, Charisse
    Gao, Haitao
    Piccolo, Carmela
    Larson, Richard A.
    Hochhaus, Andreas
    Breccia, Massimo
    DIABETES, 2013, 62 : A704 - A705
  • [23] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [24] Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION.
    Shah, Neil P.
    Saglio, Giuseppe
    Hochhaus, Andreas
    Bilmes, Robyn
    Li, Li
    Cortes, Jorge E.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [25] Primary results of the phase 4 BYOND study of bosutinib (BOS) for pretreated chronic phase (CP) chronic myeloid leukemia (CML).
    Gambacorti-Passerini, Carlo
    Abboud, Camille N.
    Gjertsen, Bjorn T.
    Brummendorf, Tim H.
    Smith, B. Douglas
    Giraldo-Castellano, Pilar
    Olsson-Stromberg, Ulla
    Saussele, Susanne
    Bardy-Bouxin, Nathalie
    Viqueira, Andrea
    Leip, Eric
    Leone, Jocelyn M.
    Rosti, Gianantonio
    Watts, Justin M.
    Giles, Frank
    Hochhaus, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [26] A MODEL-BASED ASSESSMENT OF THE BENEFITS AND RISKS OF PONATINIB VERSUS BOSUTINIB IN THIRD-LINE TREATMENT OF CHRONIC-PHASE CHRONIC MYELOID LEUKEMIA (CP-CML)
    Cartier, S.
    Parthan, A.
    McGarry, L.
    Weinstein, M.
    HAEMATOLOGICA, 2015, 100 : 149 - 150
  • [27] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Shamudheen Rafiyath
    Delong Liu
    Journal of Hematology & Oncology, 3
  • [28] First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Wei, Guoqing
    Rafiyath, Shamudheen
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2010, 3
  • [29] FINAL LASOR RESULTS: SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL CYTOGENETIC RESPONSE (CYR) TO FRONTLINE IMATINIB (IM)
    le Coutre, P. D.
    Shah, S.
    De Souza, C. A.
    Ayala, M.
    Lopez, J. L.
    Bullorsky, E.
    Shen, Z. X.
    de Oliveira, J. S. R.
    Sacha, T.
    Bendit, I.
    Liang, Z.
    Owugah, T.
    Khanna, S.
    Fellague-Chebra, R.
    Babu, K. G.
    Cortes, J. E.
    HAEMATOLOGICA, 2015, 100 : 63 - 63
  • [30] Efficacy and Tolerability of Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) Who Failed Prior Imatinib and Dasatinib Therapy: Updated Results of a Phase 2 Study
    Giles, Francis
    le Coutre, Philipp D.
    Bhalla, Kapil N.
    Ossenkoppele, Gert J.
    Alimena, Giuliana
    Haque, Ariful
    Gallagher, Neil J.
    Kantarjian, Hagop M.
    BLOOD, 2008, 112 (11) : 1110 - 1110
12345